Tendering and biosimilars: what role for value-added services? by Steven Simoens, Raymond Cheung

Get full text

Economic evaluation of biosimilars for reimbursement purposes – what, when, how? by Evelien Moorkens, Hannah Broux, Isabelle Huys, Arnold G. Vulto, Steven Simoens

Get full text

Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant by Sophie Marbaix, Sophie Marbaix, Steven Simoens, Philippe Clevenbergh, Pascal Van Bleyenbergh, Keliane Liberman, Dimitri Dehenau

Get full text

Why “American Patients First” is likely to raise drug prices outside of the United States by Monique Dabbous, Cyprien Milea, Steven Simoens, Clement François, Claude Dussart, Lylia Chachoua, Borislav Borissov, Mondher Toumi

Get full text

Value attribution for oncology combination regimens: going beyond frameworks to balance innovation, access, and affordability by Jennifer G. Gaultney, Daniel Ollendorf, Medha Sasane, Céline Fernandez, Krupa Paranjpe, Ting-Yen Chen, Hera Sandhu, Steven Simoens

Get full text

Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews by Thomas Desmet, Thomas Desmet, Sissel Michelsen, Sissel Michelsen, Elena Van den Brande, Walter Van Dyck, Steven Simoens, Isabelle Huys

Get full text

Caregivers and multidisciplinary team members’ perspectives on shared decision making in Duchenne muscular dystrophy: A qualitative study by Elise Schoefs, Thomas Desmet, Evelyn Lerinckx, Liesbeth De Waele, Sam Geuens, Conny Pelicaen, Luc Meeus, Steven Simoens, Chantal Van Audenhove, Mieke Mommen, Rosanne Janssens, Isabelle Huys

Get full text

Rule of Prevention: a potential framework to evaluate preventive interventions for rare diseases by Eddie Gibson, Daniel A. Ollendorf, Steven Simoens, David E Bloom, Federico Martinón-Torres, David Salisbury, Johan Louis Severens, Mondher Toumi, Daniel Molnar, Kinga Meszaros, Woo-Yun Sohn, Najida Begum

Get full text

Health economic evaluation of gene replacement therapies: methodological issues and recommendations by Samuel Aballéa, Katia Thokagevistk, Rimma Velikanova, Steven Simoens, Lieven Annemans, Fernando Antonanzas, Pascal Auquier, Clément François, Frank-Ulrich Fricke, Daniel Malone, Aurélie Millier, Ulf Persson, Stavros Petrou, Omar Dabbous, Maarten Postma, Mondher Toumi

Get full text

The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies by Steven Simoens, David Dodwell, Michael Hartevelt, Peter Lindgren, Peter Lindgren, Michele Pistollato, Lisa Pont, Caridad Pontes, Alexander Roediger, Antun Sablek, Eric Van Ganse, Qinyi Wang, Chris Wenger, Tim Wilsdon, Entela Xoxi, Entela Xoxi, Brian Godman, Brian Godman

Get full text

An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators by Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven Simoens, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Jörg Ruof

Get full text

The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire by Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, Walter Van Dyck, Steven Simoens, Isabelle Huys, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter G.M. Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Elaine Julian

Get full text